Lecanemab A Promising Alzheimer's Treatment Explained

Lecanemab, also known under the brand name Leqembi, has emerged as a groundbreaking therapy in the battle against Alzheimer's disease. Recently spotlighted on Korean health TV shows and conditionally approved by the U.S. FDA, this drug is generating widespread attention for its potential to slow cognitive decline. In this post, we'll explore what Lecanemab is, how it works, side effects, comparisons to Aducanumab, and more.

Table of Contents

• 1. What Is Lecanemab?
• 2. Key Benefits of Lecanemab
• 3. Important Considerations
• 4. Side Effects
• 5. Lecanemab vs. Aducanumab
• 6. How Lecanemab Is Administered
• 7. Cost and FAQs
• 8. Final Thoughts

1. What Is Lecanemab?

Lecanemab is an antibody-based drug co-developed by Eisai (Japan) and Biogen (USA) to treat early Alzheimer's disease. It targets beta-amyloid protein buildup in the brain, which is believed to contribute to disease progression. In 2023, it received conditional FDA approval and has since been introduced in select hospitals across South Korea.

2. Key Benefits of Lecanemab

• 27% Slower Cognitive Decline: Clinical trial CLN301 showed a 27% slower decline in cognitive function compared to placebo after 18 months.
• Improved Memory and Daily Function: Positive changes were noted in MMSE and CDR-SB scores.
• Amyloid Plaque Reduction: PET scans revealed significant decreases in amyloid plaques.
• Long-Term Effectiveness: Consistent treatment showed lasting results, with better outcomes when therapy starts early.

Lecanemab is particularly effective for patients in the Mild Cognitive Impairment (MCI) stage, making early diagnosis and intervention crucial.

3. Important Considerations

• More effective when administered early; minimal impact in late-stage patients
• Requires regular MRI scans before and during treatment
• Not self-administered; must be given in a clinical setting

Due to its complexity, continued monitoring and consultation with a healthcare provider are essential. Caregivers play a critical role in this process.

4. Side Effects

Common side effects include:

• ARIA (Amyloid-Related Imaging Abnormalities): Swelling or microbleeds in the brain, seen in 12-15% of patients
• Headache, Nausea, Dizziness
• Potential Vascular Inflammation

Regular brain imaging is strongly recommended during the initial treatment phase to detect any complications early.

5. Lecanemab vs. Aducanumab

Feature	Lecanemab	Aducanumab
Developers	Eisai + Biogen	Biogen
FDA Approval Year	2023	2021
Clinical Results	Proven cognitive delay	Controversial effectiveness
ARIA Incidence	Low (12–15%)	High (Approx. 35%)

6. How Lecanemab Is Administered

• Frequency: Every 2 weeks
• Method: Intravenous infusion at a hospital
• Duration per session: About 1 hour

Missed or skipped doses may reduce effectiveness, emphasizing the need for consistency.

7. Cost and FAQs

• Is it covered by insurance?
  Not yet. The cost can reach several thousand dollars annually.
• Will it be covered in the future?
  Potentially. Growing awareness and policy changes may lead to future inclusion.
• Can it be used preventatively?
  No. It's only approved for early-stage Alzheimer's.
• Does it cure Alzheimer's?
  No. It slows progression in early stages but doesn't cure the disease.
• Is it available in South Korea?
  Yes. Some hospitals have started prescribing it as of 2024.

8. Final Thoughts

Lecanemab marks a promising step forward in Alzheimer's treatment. While not a cure, it offers measurable benefits for slowing cognitive decline. Due to its high cost and strict administration process, consulting with medical professionals for early detection and timely intervention is crucial.

For families dealing with Alzheimer's, Lecanemab might represent not just a treatment option, but a meaningful hope for better quality of life.

[Check the korean ver. 레카네맙 효능 치매에 얼마나 좋을까]

TOP